United Therapeutics Corp (UTHR)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing innovative therapies for patients with chronic and life-threatening conditions. Founded in 1996, the company specializes in treatments for pulmonary arterial hypertension and related conditions, leveraging biotechnological advances to improve patient outcomes.
Company News
The artificial lung market is projected to grow from $2.78 billion in 2025 to $7.05 billion by 2034, with a 10.84% CAGR. North America dominates the market, driven by rising respiratory disease prevalence and technological advancements in medical devices.
Despite ongoing global tensions, the stock market showed resilience during the holiday season, with the S&P 500 and Nasdaq rising. Three high-growth stocks - PDD Holdings, Alphabet, and United Therapeutics - demonstrated strong performance and potential for continued gains through year-end.
MannKind reported Q2 2025 revenue of $76.5 million, slightly missing analyst estimates. The company saw growth in Afrezza inhaled insulin sales and Tyvaso DPI royalties, while increasing R&D and marketing expenses.
Several large-cap stocks, including AppLovin, Chewy, and Carvana, were among the top losers last week. The declines were attributed to factors such as weak earnings guidance, lower-than-expected sales outlook, and bearish options activity.
The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange-traded fund that provides broad exposure to the healthcare-biotech sector. The ETF tracks the NYSE Arca Biotechnology Index and has a relatively high expense ratio of 0.56%. Its top holdings include Alnylam Pharmaceuticals, Corcept Therapeutics, and United Therapeut...